BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 23104523)

  • 1. Prevalence of comorbid substance use disorder during long-term central stimulant treatment in adult ADHD.
    Torgersen T; Gjervan B; Rasmussen K; Vaaler A; Nordahl HM
    Atten Defic Hyperact Disord; 2013 Mar; 5(1):59-67. PubMed ID: 23104523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive factors for more than 3 years' duration of central stimulant treatment in adult attention-deficit/hyperactivity disorder: a retrospective, naturalistic study.
    Torgersen T; Gjervan B; Nordahl HM; Rasmussen K
    J Clin Psychopharmacol; 2012 Oct; 32(5):645-52. PubMed ID: 22926598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Managing attention-deficit/hyperactivity disorder in the presence of substance use disorder.
    Upadhyaya HP
    J Clin Psychiatry; 2007; 68 Suppl 11():23-30. PubMed ID: 18307378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of attention-deficit hyperactivity disorder in substance use disorder patients: a meta-analysis and meta-regression analysis.
    van Emmerik-van Oortmerssen K; van de Glind G; van den Brink W; Smit F; Crunelle CL; Swets M; Schoevers RA
    Drug Alcohol Depend; 2012 Apr; 122(1-2):11-9. PubMed ID: 22209385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening and imputed prevalence of ADHD in adult patients with comorbid substance use disorder at a residential treatment facility.
    Adler LA; Guida F; Irons S; Rotrosen J; O'Donnell K
    Postgrad Med; 2009 Sep; 121(5):7-10. PubMed ID: 19820269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors associated with a positive occupational outcome during long-term central stimulant treatment in adult ADHD.
    Torgersen T; Krokstad S; Vaaler AE
    Atten Defic Hyperact Disord; 2014 Dec; 6(4):281-90. PubMed ID: 24700330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Substance use disorders and ADHD: an overview of recent Dutch research].
    van Emmerik-van Oortmerssen K; Crunelle CL; Carpentier PJ
    Tijdschr Psychiatr; 2013; 55(11):861-6. PubMed ID: 24242145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A naturalistic study of the effects of pharmacotherapy on substance use disorders among ADHD adults.
    Faraone SV; Biederman J; Wilens TE; Adamson J
    Psychol Med; 2007 Dec; 37(12):1743-52. PubMed ID: 17349106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A qualitative review of issues arising in the use of psycho-stimulant medications in patients with ADHD and co-morbid substance use disorders.
    Kollins SH
    Curr Med Res Opin; 2008 May; 24(5):1345-57. PubMed ID: 18384709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methylphenidate in Adults with Attention Deficit Hyperactivity Disorder and Substance Use Disorders.
    Simon N; Rolland B; Karila L
    Curr Pharm Des; 2015; 21(23):3359-66. PubMed ID: 26088112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Substance use disorders in association with attention-deficit/hyperactivity disorder, co-morbid mental disorders, and medication in a nationwide sample.
    Steinhausen HC; Bisgaard C
    Eur Neuropsychopharmacol; 2014 Feb; 24(2):232-41. PubMed ID: 24314850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attention-deficit/hyperactivity disorder and early-onset substance use disorders.
    Wilson JJ; Levin FR
    J Child Adolesc Psychopharmacol; 2005 Oct; 15(5):751-63. PubMed ID: 16262592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Substance abuse in patients with attention-deficit hyperactivity disorder : therapeutic implications.
    Schubiner H
    CNS Drugs; 2005; 19(8):643-55. PubMed ID: 16097847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methylphenidate doses in Attention Deficit/Hyperactivity Disorder and comorbid substance use disorders.
    Skoglund C; Brandt L; D'Onofrio B; Larsson H; Franck J
    Eur Neuropsychopharmacol; 2017 Nov; 27(11):1144-1152. PubMed ID: 28935267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment seeking adults with autism or ADHD and co-morbid substance use disorder: prevalence, risk factors and functional disability.
    Sizoo B; van den Brink W; Koeter M; Gorissen van Eenige M; van Wijngaarden-Cremers P; van der Gaag RJ
    Drug Alcohol Depend; 2010 Feb; 107(1):44-50. PubMed ID: 19786328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The nature of the relationship between attention-deficit/hyperactivity disorder and substance use.
    Wilens TE
    J Clin Psychiatry; 2007; 68 Suppl 11():4-8. PubMed ID: 18307375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adolescent substance use in the multimodal treatment study of attention-deficit/hyperactivity disorder (ADHD) (MTA) as a function of childhood ADHD, random assignment to childhood treatments, and subsequent medication.
    Molina BS; Hinshaw SP; Eugene Arnold L; Swanson JM; Pelham WE; Hechtman L; Hoza B; Epstein JN; Wigal T; Abikoff HB; Greenhill LL; Jensen PS; Wells KC; Vitiello B; Gibbons RD; Howard A; Houck PR; Hur K; Lu B; Marcus S;
    J Am Acad Child Adolesc Psychiatry; 2013 Mar; 52(3):250-63. PubMed ID: 23452682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early-age clinical and developmental features associated to Substance Use Disorders in Attention-Deficit/Hyperactivity Disorder in Adults.
    Nogueira M; Bosch R; Valero S; Gómez-Barros N; Palomar G; Richarte V; Corrales M; Nasillo V; Vidal R; Casas M; Ramos-Quiroga JA
    Compr Psychiatry; 2014 Apr; 55(3):639-49. PubMed ID: 24411652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical course of comorbid substance use disorder and attention deficit/hyperactivity disorder: protocol and clinical characteristics of the INCAS study.
    Brynte C; Aeschlimann M; Barta C; Begeman AHA; Bäcker A; Crunelle CL; Daigre C; De Fuentes-Merillas L; Demetrovics Z; Dom G; López LG; Icick R; Johnson B; Joostens P; Kapitány-Fövény M; Karsinti E; Kiefer F; Konstenius M; Levin FR; Luderer M; Markus W; Matthys F; Moggi F; Palma-Alvarez RF; Paraskevopoulou M; Ramos-Quiroga JA; Schellekens A; Soravia LM; Therribout N; Thomas A; van de Glind G; van Kernebeek MW; Vollstädt-Klein S; Vorspan F; van den Brink W; Franck J
    BMC Psychiatry; 2022 Sep; 22(1):625. PubMed ID: 36151539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of prior stimulant treatment for attention-deficit/hyperactivity disorder on subsequent risk for cigarette smoking and alcohol and drug use disorders in adolescents.
    Wilens TE; Adamson J; Monuteaux MC; Faraone SV; Schillinger M; Westerberg D; Biederman J
    Arch Pediatr Adolesc Med; 2008 Oct; 162(10):916-21. PubMed ID: 18838643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.